| Title |
An update on PARP inhibitors for the treatment of cancer
|
|---|---|
| Published in |
OncoTargets and therapy, February 2015
|
| DOI | 10.2147/ott.s30793 |
| Pubmed ID | |
| Authors |
Sarah Benafif, Marcia Hall |
| Abstract |
The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers. This article attempts to summarize the rationale and theory behind PARPi, the clinical trials already reported, as well as ongoing studies designed to determine the role of PARPi in patients with and without germline mutations of BRCA genes. Future plans for PARPi both as monotherapy and in combination with standard cytotoxics, other biological agents, and as radiosensitizers are also covered. The widening scope of PARPi adds another important targeted agent to the growing list of molecular inhibitors; future and ongoing trials will identify the most effective role for PARPi, including for patients other than BRCA germline mutation carriers. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Czechia | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 154 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 34 | 22% |
| Researcher | 24 | 15% |
| Student > Bachelor | 18 | 11% |
| Student > Master | 13 | 8% |
| Student > Postgraduate | 12 | 8% |
| Other | 23 | 15% |
| Unknown | 33 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 41 | 26% |
| Biochemistry, Genetics and Molecular Biology | 37 | 24% |
| Medicine and Dentistry | 25 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Immunology and Microbiology | 5 | 3% |
| Other | 9 | 6% |
| Unknown | 34 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2021.
All research outputs
#5,221,769
of 25,582,611 outputs
Outputs from OncoTargets and therapy
#253
of 2,967 outputs
Outputs of similar age
#68,935
of 362,274 outputs
Outputs of similar age from OncoTargets and therapy
#3
of 18 outputs
Altmetric has tracked 25,582,611 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,274 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.